MoonLake Immunotherapeutics MLTX Cash Flow Statement (2021-2026)

NASDAQ MLTX
$15.01 -0.18 (-1.18%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

MoonLake Immunotherapeutics Quarterly Cash Flow Statement

Periods 22 quarters
Latest Jun 2026

MoonLake Immunotherapeutics reported cash from operations of -$55.56M and free cash flow of -$55.56M for the quarter ended Jun 2026, down 1.9% year over year. This cash flow statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-6.29M-53.64M-15.88M-17.42M-14.74M-16.47M-12.22M-12.35M-11.62M-7.89M-13.97M-24.76M-36.11M-46.40M-40.56M-56.05M-70.69M-63.02M-69.71M-61.80M
Share-based CompensationStock Comp.
1.86M9.05M1.99M2.48M2.59M2.60M2.58M1.50M1.43M1.61M1.68M1.83M1.84M1.93M2.29M3.31M3.71M3.59M13.36M2.55M
Cash from OperationsCash from Ops.
-2.02M-35.18M-14.19M-20.76M-9.35M-11.60M-9.02M-12.16M-9.25M-12.34M-14.95M-27.89M-25.28M-48.47M-38.14M-54.53M-44.54M-58.79M-66.29M-55.56M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.33M0.37M0.32M0.38M0.40M0.72M0.78M0.72M0.84M0.90M
Change in Working Capital
Change in Account PayablesChange Payables
0.21M1.57M2.25M-3.03M0.27M-0.80M3.57M0.53M-0.96M-1.57M1.65M1.66M5.57M-1.72M3.01M5.07M8.20M4.27M-6.17M-6.34M
Change in Accured ExpensesChange Accured Exp.
2.10M4.51M-1.35M-0.11M1.90M2.24M-3.95M-0.67M1.42M2.87M-2.81M1.69M2.11M4.17M-1.56M-1.81M12.86M-6.90M7.12M3.79M
Investing Activities
Capital ExpendituresCapex
0.01M0.05M0.02M-2.001.000.28M0.21M0.13M0.18M1.70M-0.00M-1.11M0.75M-0.00M
Change in Acquisitions & DivestmentsChange Acquisitions
9.90M19.65M12.68M1.36M117.15M59.12M-1.30M87.59M-0.21M144.83M205.91M88.40M29.26M59.17M59.07M
Cash from Investing ActivitiesCash from Investing
-0.01M-0.05M-0.02M2.00-42.23M9.90M19.65M12.68M-174.38M116.87M-28.80M-87.74M58.28M-147.33M56.25M88.25M88.40M-29.91M0.10M0.32M
Financing Activities
Other financing activitiesOther financing
0.11M0.00M-0.00M0.00M482.45M0.09M52.45M0.10M0.38M71.92M0.17M0.55M
Cash from Financing ActivitiesCash from Financing
0.50M43.26M15.00M104.69M0.00M451.29M28.42M50.98M0.18M0.15M73.12M0.48M72.39M30.64M234.62M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
14.60M52.54M6.01M44.31M
Additional items
Exchange Rate EffectFX Effect
-0.00M0.00M-0.01M-0.05M0.07M-0.01M-535.00-0.14M0.01M0.06M0.05M-0.02M-0.33M0.42M-0.09M1.39M-0.28M0.09M-0.48M0.03M
Change in Cash
-1.53M8.04M0.80M83.87M-51.50M-1.70M10.62M451.66M-183.62M133.00M7.27M-115.65M32.86M-195.23M91.14M35.12M44.05M-16.22M-36.03M179.41M
Free Cash FlowFCF
-2.03M-35.23M-14.20M-20.76M-9.35M-11.60M-9.02M-12.16M-9.25M-12.63M-15.16M-27.89M-25.41M-48.65M-39.84M-54.53M-43.43M-58.79M-67.03M-55.56M
Net Cash FlowNCF
-1.53M8.04M0.80M83.92M-51.58M-1.69M10.62M451.80M-183.63M132.94M7.23M-115.63M33.19M-195.65M91.23M33.72M44.34M-16.31M-35.54M179.39M